These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15897595

  • 1. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
    Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL.
    Clin Cancer Res; 2005 May 15; 11(10):3930-8. PubMed ID: 15897595
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR.
    Clin Cancer Res; 2003 Jul 15; 9(7):2510-9. PubMed ID: 12855625
    [Abstract] [Full Text] [Related]

  • 3. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
    Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR.
    Lung Cancer; 2008 Jun 15; 60(3):347-54. PubMed ID: 18096271
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.
    Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL.
    Bioconjug Chem; 2007 Jun 15; 18(4):1325-31. PubMed ID: 17583927
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A, Iversen PL.
    Curr Opin Pharmacol; 2005 Oct 15; 5(5):550-5. PubMed ID: 16087398
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.
    Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL.
    J Pharm Sci; 2002 Apr 15; 91(4):1009-18. PubMed ID: 11948540
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.
    Devi GR.
    Methods Mol Biol; 2009 Apr 15; 542():351-61. PubMed ID: 19565912
    [Abstract] [Full Text] [Related]

  • 15. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats.
    Arora V, Hannah TL, Iversen PL, Brand RM.
    Pharm Res; 2002 Oct 15; 19(10):1465-70. PubMed ID: 12425463
    [Abstract] [Full Text] [Related]

  • 16. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007 Oct 15; 26 Suppl 1():3-106. PubMed ID: 17365137
    [Abstract] [Full Text] [Related]

  • 17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar 15; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.
    Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1045-54. PubMed ID: 18301895
    [Abstract] [Full Text] [Related]

  • 19. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
    Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM.
    Bioconjug Chem; 2005 Nov 15; 16(4):959-66. PubMed ID: 16029037
    [Abstract] [Full Text] [Related]

  • 20. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW.
    Prostate; 2005 Jun 01; 63(4):369-84. PubMed ID: 15937962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.